Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal

Ecnoglutide, which Pfizer licensed from Sciwind Biosciences, is already approved in China for type 2 diabetes mellitus, and a marketing application for weight loss has been accepted by regulatory authorities in the country.

Scroll to Top